NRG Therapeutics

NRG Therapeutics is a clinical-stage drug discovery company developing oral, CNS-penetrant small molecules designed to inhibit the mitochondrial permeability transition pore (mPTP). These disease-modifying treatments aim to rectify mitochondrial function and slow the progression of neurodegenerative disorders such as Parkinson’s and amyotrophic lateral sclerosis (ALS). The company's lead candidate, NRG5051, entered Phase 1 clinical trials in 2026.